ASCENTAGE PHARMA GROUP INTERNATIONAL
Close on Oct 19, 2026
About Ascentage Pharma Group International
Pharmaceutical Preparations, SIC 2834
Ascentage Pharma Group International is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and pharmaceutical products. The company develops clinical and preclinical drug candidates, with primary commercial products including Olverembatinib and Lisaftoclax. Its operations center on pharmaceutical product sales, commercialization rights agreements, intellectual property licensing, and management services. The company provides its pharmaceutical products to patients needing medical treatment, while also collaborating with and serving biopharmaceutical industry partners such as Innovent and Takeda.
The enterprise maintains substantive business operations in China and the United States, alongside clinical research activities that receive government tax credits and subsidies in Australia. It has manufacturing facilities and conducts operations through multiple subsidiaries. The company is incorporated in the Cayman Islands, with its principal executive offices located in Suzhou, China, and an additional corporate office located in Rockville, Maryland.
Summary of the business section of Ascentage Pharma Group International's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ASCENTAGE PHARMA GROUP INTERNATIONAL
- Founded
- 2009
- Headquarters
- Suzhou , Jiangsu, China
- Address
- 68 Xinqing Road, Suzhou Industrial Park
- Phone
- 86 512 8555 7777
- Website
- ascentage.com
- Employees
- 767, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young Hua Ming LLP, China
Stock & identifiers
- Ticker
- AAPG
- Exchange
- Nasdaq
- IPO date
- Jan 24, 2025
- Shares outstanding
- 373M, Apr 1, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2023311
- CUSIP
- 04390B105
- ISIN
- US04390B1052
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dajun Yang | Chairman and CEO, Director | 37,742,091 |
| Faical Miyara | Chief Business Officer | – |
| Yifan Zhai | Chief Medical Officer | 37,742,091 |
| Veet Misra | Chief Financial Officer | – |
| Jin Cao | Chief Accounting Officer | 5,400 |
| Thomas J. Knapp | SVP/General Counsel | 362,444 |
| Shaomeng Wang | Director | 10,053,943 |
| Ren Wei | Director | 8,964 |
| Marc E. Lippman | Director | 21,174 |
| David Sidransky | Director | 10,641 |
| Marina Bozilenko | Director | – |
| Debra Yu | Director | – |
| Simon Dazhong Lu | Director | 41,457 |
| Changqing Ye | Director | 8,964 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 767 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 24, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 21, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |